DAPA-HF blazing a trail for sodium-glucose co-transporter-2 inhibitors in heart failure

Phase III trial looked at the outcomes of AstraZeneca’s Farxiga use in patients with heart failure with reduced ejection fraction, in patients both with and without diabetes.